897-P: Insulin-Sensitizing Effects of Efruxifermin Improve Glycemic Control in Patients with MASH and Type 2 Diabetes
Notice bibliographique
Résumé
Introduction & Objective: In phase 2 studies, efruxifermin (EFX), a long-acting bivalent Fc-FGF21 analog, significantly reduced steatohepatitis and fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH). Many patients with MASH have type 2 diabetes (T2D), which is increasingly treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs). We investigated the effects of EFX in patients with T2D, including those being treated with GLP-1RAs. Methods: The effects of EFX on markers of insulin sensitivity and glycemic control were studied in 5 independent cohorts of patients with T2D and MASH with liver fibrosis, ranging from F1 to F4 (compensated cirrhosis). EFX treatment ranged from 12 to 36 weeks. Endpoints included changes in markers of glucose metabolism and insulin sensitivity, lipoprotein profile, steatohepatitis, and fibrosis, as well as use of T2D medications. Results: EFX consistently improved markers of insulin sensitivity and glucose metabolism on top of stable T2D therapies, including GLP-1RA. EFX was also associated with a trend towards weight loss. Markers of liver injury, steatohepatitis, and fibrosis were improved consistently by EFX, even in patients on stable GLP-1RA therapy. EFX was safe and well tolerated in all trials; the most common AEs were mild-moderate gastrointestinal events. Conclusions: EFX has consistently improved markers of whole-body glucose and lipid metabolism in patients with MASH and T2D, even on top of stable T2D medications including GLP-1RA. EFX-mediated insulin sensitization may potentiate effects of insulin or insulin secretagogues, possibly enabling patients to reduce use of insulin and/or other T2D medications to mitigate weight gain, incidence of hypoglycemia, or other side effects. Disclosure K.J. Lucas: Research Support; Akero Therapeutics, Inc. S.A. Harrison: Other Relationship; Akero Therapeutics, Inc. Consultant; 89bio, Inc., Agilos Therapeutics. Other Relationship; Altimmune Inc. Advisory Panel; Arrowhead Pharmaceuticals, Inc. Consultant; Asteroid Therapeutics, Bluejay Therapeutics. Research Support; Bristol-Myers Squibb Company. Consultant; BOEHRINGER INGELHEIM PHARMA, INC, Boxer Capital. Advisory Panel; Chronwell Inc. Consultant; Corcept Therapeutics, ECCOGENE, INC, DEXCOM, INC. Advisory Panel; ECHOSENS NORTH AMERICA, INC. Consultant; Enyo Pharma. Other Relationship; GALECTIN THERAPEUTICS, INC. Consultant; GALECTO, INC, HEPAGENE THERAPEUTICS. Other Relationship; HEPION PHARMACEUTICALS, INC, Gilead Sciences, Inc. Consultant; GlaxoSmithKline plc. Other Relationship; Hepta Bio. Consultant; HISTOINDEX PTE. LTD. Advisory Panel; Humana. Other Relationship; Madrigal Pharmaceuticals, Inc., Intercept Pharmaceuticals, Inc. Advisory Panel; Inventiva Pharma. Other Relationship; Ionis Pharmaceuticals, Medpace. Stock/Shareholder; MGGM THERAPEUTICS LLC. Consultant; NEUROBO PHARMACEUTICALS INC. Other Relationship; NGM BIOPHARMACEUTICALS, INC, NORTHSEA THERAPEUTICS B.V., Novo Nordisk. Research Support; Pfizer Inc. Consultant; PIPER SANDLER & CO. Other Relationship; POXEL. Consultant; Regeneron Pharmaceuticals Inc. Other Relationship; Sagimet Biosciences, Sonic Incytes. Consultant; Takeda Canada. Other Relationship; Terns Pharmaceuticals. Consultant; TRAMONTANE THERAPEUTICS INC (Kriya). Other Relationship; Viking Therapeutics. Consultant; CALIMETRIX, LLC. D. Chan: Employee; Akero Therapeutics, Inc. E.J. Tillman: Employee; Akero Therapeutics, Inc. Stock/Shareholder; Akero Therapeutics, Inc. A. Moulton: Employee; Akero Therapeutics, Inc. Stock/Shareholder; Akero Therapeutics, Inc. B. de Temple: Employee; Akero Therapeutics, Inc. Stock/Shareholder; Akero Therapeutics, Inc. A. Zari: Employee; Akero Therapeutics, Inc. Stock/Shareholder; Akero Therapeutics, Inc. R. Shringarpure: Employee; Akero Therapeutics, Inc. Stock/Shareholder; Akero Therapeutics, Inc. T. Rolph: Stock/Shareholder; Akero Therapeutics, Inc., Pfizer Inc. A. Cheng: Employee; Akero Therapeutics, Inc. K. Yale: Employee; Akero Therapeutics, Inc. Funding Akero Therapeutics Inc
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,000 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,000 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».